Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.520
-0.090 (-5.59%)
At close: Aug 14, 2025, 4:00 PM
1.520
0.00 (0.00%)
After-hours: Aug 14, 2025, 6:30 PM EDT
Protalix BioTherapeutics Revenue
Protalix BioTherapeutics had revenue of $15.66M in the quarter ending June 30, 2025, with 16.21% growth. This brings the company's revenue in the last twelve months to $61.95M, up 62.79% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.
Revenue (ttm)
$61.95M
Revenue Growth
+62.79%
P/S Ratio
1.98
Revenue / Employee
$290,836
Employees
213
Market Cap
121.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 53.40M | -12.10M | -18.47% |
Dec 31, 2023 | 65.49M | 17.86M | 37.48% |
Dec 31, 2022 | 47.64M | 9.29M | 24.22% |
Dec 31, 2021 | 38.35M | -24.55M | -39.03% |
Dec 31, 2020 | 62.90M | 8.21M | 15.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PLX News
- 6 hours ago - Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 hours ago - Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PRNewsWire
- 7 days ago - Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 - PRNewsWire
- 24 days ago - Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer - PRNewsWire
- 6 weeks ago - Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® - PRNewsWire
- 3 months ago - Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - PRNewsWire
- 3 months ago - Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results - PRNewsWire